Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Viasat
VSAT
$12B
| $18.4M | 0.02% |
+277,993
| New | +$18.3M |
|
902
AutoZone
AZO
$49.7B
| $18.4M | 0.02% |
32,243
-70,557
| -69% | -$45.9M |
|
903
International Flavors & Fragrances
IFF
$21.4B
| $18.4M | 0.02% |
136,200
+133,600
| +5,138% | +$18.1M |
|
904
Vera Bradley
VRA
$96.7M
| $18.4M | 0.02% |
1,878,115
-13,685
| -0.7% | -$120K |
|
905
Tenaris
TS
$26.6B
| $18.4M | 0.02% |
589,300
-363,799
| -38% | -$11.5M |
|
|
KMG
906
DELISTED
KMG Chemicals Inc
KMG
| $18.3M | 0.02% |
377,000
-4,500
| -1% | -$231K |
|
|
MIME
907
DELISTED
Mimecast Limited
MIME
| $18.3M | 0.02% |
684,600
+310,500
| +83% | +$7.79M |
|
|
CAJ
908
DELISTED
Canon, Inc.
CAJ
| $18.3M | 0.02% |
538,700
-451,100
| -46% | -$15.2M |
|
|
CUNB
909
DELISTED
CU Bancorp
CUNB
| $18.3M | 0.02% |
505,300
+295,300
| +141% | +$10.9M |
|
|
BFS
910
Saul Centers
BFS
$850M
| $18.2M | 0.02% |
314,400
+10,600
| +3% | +$635K |
|
|
AAMI
911
Acadian Asset Management
AAMI
$3.27B
| $18.2M | 0.02% |
+1,225,600
| New | +$18.1M |
|
|
BKMU
912
DELISTED
Bank Mutual Corp
BKMU
| $18.2M | 0.02% |
1,990,111
-50,042
| -2% | -$464K |
|
|
CLCT
913
DELISTED
Collectors Universe
CLCT
| $18.2M | 0.02% |
731,119
+14,700
| +2% | +$380K |
|
914
Essent Group
ESNT
$6.14B
| $18.1M | 0.02% |
487,300
+4,500
| +0.9% | +$165K |
|
915
Mercer International
MERC
$32.3M
| $18.1M | 0.02% |
1,573,200
+127,400
| +9% | +$1.47M |
|
916
Calix
CALX
$2.51B
| $18M | 0.02% |
2,626,018
+214,418
| +9% | +$1.45M |
|
|
CSFL
917
DELISTED
CenterState Bank Corporation Common Stock
CSFL
| $17.9M | 0.02% |
722,000
+124,300
| +21% | +$3.09M |
|
918
Vanda Pharmaceuticals
VNDA
$314M
| $17.9M | 0.02% |
1,097,950
+158,700
| +17% | +$2.29M |
|
|
FSP
919
Franklin Street Properties
FSP
$46.3M
| $17.9M | 0.02% |
1,612,900
+61,700
| +4% | +$714K |
|
920
Reading International Class A
RDI
$32.7M
| $17.8M | 0.02% |
1,102,973
+10,473
| +1% | +$163K |
|
921
AES
AES
$10.5B
| $17.7M | 0.02% |
+1,597,386
| New | +$18.3M |
|
922
eHealth
EHTH
$39.7M
| $17.7M | 0.02% |
943,600
+64,700
| +7% | +$1.03M |
|
|
SNR
923
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
| $17.6M | 0.02% |
1,754,900
+494,200
| +39% | +$4.96M |
|
|
FPO
924
DELISTED
First Potomac Realty Trust
FPO
| $17.6M | 0.02% |
1,585,700
+218,700
| +16% | +$2.38M |
|
925
Chord Energy
CHRD
$7.53B
| $17.6M | 0.02% |
+2,182,800
| New | +$23.9M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.